COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE® TEST FOR POSTMENOPAUSAL WOMEN WITH HR+/HER2-NODE-POSITIVE EARLY BREAST CANCER IN CANADA

被引：0
|
作者：
Berdunov, V [1 ]
Richardson, R. [2 ]
Millen, S. [3 ]
机构：
[1] PHMR Ltd, London, England
[2] Exact Sci, Dartmouth, NS, Canada
[3] Exact Sci, London, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE194
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE® TEST FOR HR+/HER2-EARLY-STAGE BREAST CANCER IN THE US
    Berdunov, V
    Carter, Cuyun G.
    Laws, E.
    Luo, R.
    Russell, C.
    Campbell, S.
    Force, J.
    Abdou, Y. G.
    VALUE IN HEALTH, 2022, 25 (07) : S352 - S353
  • [2] Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer
    Berdunov, Vladislav
    Millen, Steve
    Paramore, Andrew
    Hall, Peter
    Perren, Timothy
    Brown, Rebecca
    Griffin, Jane
    Reynia, Sarah
    Fryer, Nina
    Longworth, Louise
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 591 - 604
  • [3] Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.
    Berdunov, Vladislav
    Millen, Steve
    Paramore, Andrew
    Reynia, Sarah
    Fryer, Nina
    Griffin, Jane
    Georges, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
    Berdunov, Vladislav
    Millen, Steve
    Paramore, Andrew
    Griffin, Jane
    Reynia, Sarah
    Fryer, Nina
    Brown, Rebecca
    Longworth, Louise
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 619 - 633
  • [5] Correlation of the oncotype DX breast recurrence score and the ki-67 IHC MIB-1 pharmDX score in HR+, HER2-, node-positive early breast cancer.
    Crager, Michael
    Wijayawardana, Sameera R.
    Gruver, Aaron M.
    Blacklock, Andrea
    Baehner, Frederick L.
    Russell, Christy
    Sapunar, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score ® Test from a US Societal Perspective
    Berdunov, Vladislav
    Carter, Gebra Cuyun
    Laws, Ewan
    Luo, Roger
    Russell, Christy A.
    Campbell, Sara
    Abdou, Yara
    Force, Jeremy
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2024, 16 : 471 - 482
  • [7] Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2-Node-Negative Breast Cancer in the Netherlands
    de Jongh, Felix E.
    Efe, Reva
    Herrmann, Kirsten H.
    Spoorendonk, Jelle A.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2022, 2022
  • [8] COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX® TEST TO REDUCE UNDER-TREATMENT IN PATIENTS WITH HR+/HER2-NODE NEGATIVE EARLY-STAGE BREAST CANCER AND GRADE 2 T1C TUMOURS
    Berdunov, V
    Millen, S.
    Paramore, A.
    Reynia, S.
    Fryer, N.
    Griffin, J.
    Longworth, L.
    VALUE IN HEALTH, 2022, 25 (12) : S128 - S129
  • [9] Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer
    Tsoi, D. T.
    Inoue, M.
    Kelly, C. M.
    Verma, S.
    Pritchard, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] COST-EFFECTIVENESS OF ALPELISIB PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HR+/HER2ADVANCED BREAST CANCER (ABC) IN OMAN
    Soliman, D.
    Yasar, N.
    Hawkshaw, S.
    VALUE IN HEALTH, 2023, 26 (06) : S68 - S68
12345